15 Jun 2022 13:23
SourceBio International plc
('SourceBio', the 'Company' or the 'Group')
Result of Annual General Meeting
SourceBio confirms that all resolutions put to the 2022 Annual General Meeting held on the 15 June wereduly passed by the required majority.
Voting on the resolutions was as follows:
Resolution | Description | For | Against | Withheld |
1 | To receive and approve the Company's Annual Report and Accounts for the financial year ended 31 December 2021 together with the Directors' Report (including the Strategic Report) and the Auditor's Report. | 54,501,649 | 1,500 | 500 |
2 | To receive and approve the Directors' Remuneration Report for the financial year ended 31 December 2021. | 54,496,283 | 6,866 | 500 |
3 | To re-appoint RSM UK Audit LLP as auditor of the Company and to authorise the Directors to fix their remuneration. | 54,501,499 | 1,650 | 500 |
4 | To authorise the Directors generally to allot ordinary shares up to the specified limit. | 54,488,761 | 14,388 | 500 |
5 * | To empower the Directors to issue shares free from statutory pre-emption rights up to the specified limit. | 54,454,524 | 20,202 | 28,923 |
6 * | To authorise the Directors to make market purchases of ordinary shares to the specified limit. | 54,497,703 | 5,446 | 500 |
* Special Resolution
A trading update was released at 7.00am this morning.
Notes:
· Any proxy appointments which gave direction to the Executive Chairman have been included in the "for" column;
· The total number of shares in issue is 74,183,038
Contacts:
SourceBio International plc | www.sourcebiointernational.com | |
Jay LeCoque, Executive Chairman | Via Walbrook PR | |
Tony Ratcliffe, Chief Financial Officer | ||
Liberum (Nominated Advisor and Broker) | Tel: 020 3100 2000 | |
Richard Lindley / William Hall / Miquela Bezuidenhoudt | ||
Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services with clients in the pharmaceutical, healthcare, clinical, drug development and life sciences research industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:
● | Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland, including Digital Pathology
|
● | Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America
|
● | Stability Storage - shelf-life testing services and equipment service and validation for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA
|
● | Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation.
|
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.